- Investing.com
Market Dynamics | Learn about AdaptHealth's resilience against potential GLP-1 drug impacts and Medicare rate changes, with analyst price targets ranging from $13 to $16 |
Strategic Initiatives | Delve into AdaptHealth's efforts to strengthen core competencies, simplify operations, and reduce debt, aiming for sustainable long-term growth |
Financial Outlook | Explore AdaptHealth's conservative 2024 guidance, projecting revenue of $3.25-$3.35 billion and adjusted EBITDA of $650-$710 million |
Adaptive Healthcare | AdaptHealth navigates the evolving home healthcare landscape, focusing on Sleep, Respiratory, and Diabetes care segments amidst industry shifts |
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Metrics to compare | AHCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAHCOPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.0x | −5.5x | −0.6x | |
PEG Ratio | 0.00 | −0.10 | 0.00 | |
Price / Book | 0.9x | 2.7x | 2.6x | |
Price / LTM Sales | 0.4x | 1.5x | 3.2x | |
Upside (Analyst Target) | 24.5% | 34.4% | 40.8% | |
Fair Value Upside | Unlock | 8.2% | 5.9% | Unlock |